Stomach pain on GLP-1 medications

What "abdominal pain" counts in the tables

The tables group related terms differently, so the numbers are not like for like. In the Wegovy® table, abdominal pain includes upper and lower abdominal pain, gastrointestinal pain, tenderness, discomfort and epigastric discomfort. In the Zepbound® table it includes abdominal discomfort, upper and lower abdominal pain and tenderness. The Saxenda® table lists abdominal pain and upper abdominal pain as separate rows ^[2][3][6].

Each label also reminds readers that rates from one drug’s trials cannot be compared directly with another drug’s trials.

Rates against placebo, label by label

European and Canadian product information

In the European Wegovy® summary, abdominal pain over the 68-week STEP 1–4 trials occurred in 19.7% on semaglutide against 10% on placebo, and most stomach events were described as mild to moderate and of short duration. Its leaflet lists stomach pain as very common, meaning more than 1 in 10 people ^[8].

The European Mounjaro® leaflet lists abdominal pain as very common in people treated for weight management and common in adults treated for type 2 diabetes ^[9]. The Canadian Zepbound® monograph, revised in June 2026, gives 8.9%, 9.3% and 10.4% on 5, 10 and 15 mg against 5.1% on placebo, consistent with the US label ^[10].

When it tends to be reported

The Mounjaro® and Zepbound® labels say most reports of nausea, vomiting and diarrhea happened during dose escalation and decreased over time, and that most people who stopped Zepbound® because of side effects did so in the first few months, because of stomach reactions. The Wegovy® label says its stomach-related reactions, abdominal pain among them, were most frequently reported during dosage escalation ^[1][2][3].

In the Mounjaro® cardiovascular outcomes trial, abdominal pain was reported by 10% of the 6,647 adults treated; the label lists it among the reactions that differed from its other trials and gives no comparison figure ^[1].

Pain the labels treat as a warning sign

• Pancreatitis: persistent or severe pain in the stomach area, sometimes spreading to the back, with or without nausea or vomiting. In the Mounjaro® clinical studies, acute pancreatitis was confirmed in 13 people (0.23 per 100 years of exposure) versus 3 on comparators (0.11) ^[1].
• Gallbladder problems: pain in the upper stomach, yellowing of the skin or eyes, fever or clay-colored stools. Acute gallbladder disease was reported in 0.6% of people on Mounjaro® versus 0% on placebo ^[1].
• Severe stomach reactions: in Mounjaro® trials, 1.3%, 0.4% and 1.2% on the three doses versus 0.9% on placebo; in Zepbound® trials, 1.7% to 3.1% versus 1% ^[1][2].
• Bowel blockage: post-marketing reports in the labels include ileus, intestinal obstruction and severe constipation with fecal impaction ^[1][3].
• Appendicitis: the Wegovy® label reports it in 0.5% of adults versus 0.2% on placebo in its weight-reduction trials ^[3].

What published research adds

Two kinds of study look at the serious end of the list, and they do not fully agree. A 2025 meta-analysis in Gastroenterology pooled 55 randomised placebo-controlled trials with 106,395 participants. GLP-1 medicines increased gallstones (risk ratio 1.46, about 2 more cases per 1,000) and probably increased reflux, but probably had little or no effect on pancreatitis, bowel obstruction, ileus or gastroparesis ^[11].

A 2023 research letter in JAMA used US insurance claims from people with obesity but no diabetes, comparing new users of semaglutide or liraglutide with users of bupropion-naltrexone, a weight-loss medicine that does not act on GLP-1. GLP-1 users had a higher risk of pancreatitis (hazard ratio 9.09) and bowel obstruction (4.22), with wide confidence intervals, and no clear difference in biliary disease ^[12].

The designs explain part of the gap. Trials randomise people but may not run long enough, or enrol enough people, to catch rare events; claims studies follow real use but rely on billing codes and cannot prove cause. The authors of the claims study call these events rare. Neither changes the practical point: the warning-sign pains above need prompt attention.

Other common causes

MedlinePlus notes that almost everyone has abdominal pain at some point and that most of it is not serious. Less serious causes include constipation, irritable bowel syndrome, food intolerance, food poisoning and stomach flu. Constipation is also among the most common GLP-1 reactions, so it is worth considering first when pain comes with infrequent or hard stools ^[13].

MedlinePlus also explains why intensity can mislead: gas or a stomach virus can hurt a lot, while early appendicitis may cause only mild pain. Pain spread over more than half the belly is more typical of a virus, indigestion or gas; pain in one spot points more towards a single organ such as the appendix, gallbladder or stomach; pain in waves is often linked to kidney stones or gallstones ^[13].

What general guidance says helps

• For mild pain, MedlinePlus suggests sipping water or other clear fluids, avoiding solid food for the first few hours, and returning to small amounts of mild food after vomiting. It adds that people with diabetes should check their blood sugar often in this situation ^[13].
• If the pain is high up and comes after meals, MedlinePlus says antacids may help, especially with heartburn or indigestion, and suggests avoiding citrus, fatty or fried foods, tomato products, caffeine, alcohol and fizzy drinks ^[13].
• For prevention, MedlinePlus lists drinking water through the day, eating smaller meals more often, regular exercise, limiting foods that produce gas and eating plenty of fruit and vegetables ^[13].
• Medicines: MedlinePlus asks you not to take any medicine for abdominal pain without talking to your provider, and the GLP-1 labels ask you to tell your provider about everything you take ^[3][13].

Describing pain so it can be judged

Clinicians usually want the same few details: where the pain is (upper, lower, one side, spreading to the back), how strong it is on a 0 to 10 scale, whether it comes and goes or stays, how it relates to meals and to your dose day, and what came with it, such as vomiting, fever, constipation or a change in stool colour. MedlinePlus adds what makes it better or worse and whether it wakes you at night ^[13].

These details are hard to recall a week later. A note written on the day, with a time, is more reliable than memory and helps tell an expected reaction apart from a warning sign.

Ozempic®, Wegovy®, Rybelsus® and Saxenda® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company, and Foundayo™ is a trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Novo Nordisk or Eli Lilly.